022 - A 10 Minute Treatment for Depression : DMT in a Phase 2a Study

We discuss a Phase 2a clinical trial investigating the use of intravenous DMT (SPL026) as a fast-acting treatment for major depressive disorder. The research demonstrates that a single dose, paired with psychotherapeutic support, leads to a rapid and significant reduction in symptoms that can last up to three months. Unlike traditional antidepressants that take weeks to work, this short-acting psychedelic provides an immediate effect and was found to be generally safe and well-tolerated by participants. Dr. Steve’s commentary emphasizes that this modern research addresses a forty-year gap in psychedelic studies caused by previous political and regulatory restrictions. Overall, the findings suggest that DMT could offer a highly efficient alternative for patients who do not respond well to conventional therapies.

Check out simplyherbals.net and tell them Topics in Palliative Medicine sent you!